Trial Profile
A Phase I, Randomized, Double-blind, Placebo- and Active-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of DWP16001 Following Oral Administration in Healthy Male Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 Apr 2022
Price :
$35
*
At a glance
- Drugs Enavogliflozin (Primary)
- Indications Metabolic disorders; Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Daewoong Pharmaceutical
- 08 Apr 2022 Results published in the British Journal of Clinical Pharmacology
- 19 Aug 2019 Status changed from recruiting to completed.
- 12 Dec 2017 New trial record